Latest News and Press Releases
Want to stay updated on the latest news?
-
12 September 2023 Clinigen launches NaviGATE: an educational programme for rare diseasepatients and organisations Accessing hard to reach medicines for people who need them most...
-
10 August 2023 Clinigen divests global rights to four cancer support therapies to CNX Therapeutics Clinigen Limited (‘Clinigen’), the global pharmaceutical services company, has completed the...
-
23 January 2023 Clinigen divests Proleukin® to Iovance Biotherapeutics for £166.7 million The deal includes a £41.7 million milestone payment and double-digit Proleukin® global sales royalties ...
-
20 December 2022 Clinigen initiates a Managed Access Program for relugolix in Europe for the treatment of advanced hormone-sensitive prostate cancer Clinigen Limited (‘Clinigen’), the global...
-
8 December 2022Clinigen notes results from the MIROCALS trial investigating low dose Proleukin® (aldesleukin) in patients with amyotrophic lateral sclerosisClinigen Limited (‘Clinigen’), the global...
-
November 29, 2022 Clinigen adds pharmacovigilance capabilities with acquisition of Drug Safety Navigator Clinigen Limited (‘Clinigen’ or the ‘Company’), the global pharmaceutical services...
-
24 May 2022 Clinigen expands US site capacity in response to growing demand for Clinical Supplies Management services Clinigen Limited (‘Clinigen’ or the ‘Company’), the global pharmaceutical...